Left Ventricular Hypertrophy and Obesity: Only a Matter of Fat?

High Blood Pressure and Cardiovascular Prevention

Volumn 22, Issue 1, 2015, Pages 29-41

  Murdolo, Giuseppe ^a   Angeli, Fabio ^b   Reboldi, Gianpaolo ^b   Di Giacomo, Letizia ^a   Aita, Adolfo ^a   Bartolini, Claudia ^c   Vedecchia, Paolo ^a  

^a Ospedale Assisi   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Hospital Media Valle Del Tevere   (Italy)

Author keywords

Adipose tissue; Concentric left ventricular hypertrophy; Eccentric left ventricular hypertrophy; Epicardial fat; Hypertension; Insulin resistance; Left ventricular mass; Obesity

Indexed keywords

FAT;

ADIPOSE TISSUE; ARTICLE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; DIASTOLIC HEART FAILURE; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS; OBESITY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE; WEIGHT REDUCTION; ANIMAL; COMPLICATION; ENERGY METABOLISM; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; ENERGY METABOLISM; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; OBESITY; PROGNOSIS; RISK FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84924045675     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0068-x     Document Type: Article

References (105)

1. WHO Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva: World Health Organisation; 1998.
2. NIH Conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115:956–61.
3. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–105.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.
5. Sjostrom LV. Mortality of severely obese subjects. Am J Clin Nutr. 1992;55(2 Suppl):516S–23S.
6. Gomez-Ambrosi J, Silva C, Galofre JC, Escalada J, Santos S, Millan D, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012;36(2):286–94.
7. Kuk JL, Ardern CI, Church TS, Sharma AM, Padwal R, Sui X, et al. Edmonton Obesity Staging System: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36(4):570–6.
8. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059–66.
9. Iacobellis G, Sharma AM. Cardiovascular disease and obesity. In: Williams G, Fruhbeck G, editors. Obesity, science to practice. USA: Wiley-Blackwell Ltd; 2009. p. 287–320.
10. Chadwick J, Mann W. The medical works of Hyppocrates. Aphorisms, sect. II 44. Springfield: Charles C Thomas Co; 1950. p. 154.
11. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898–918.
12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;14(444):881–7.
13. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008;94:206–18.
14. Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev. 2008;24:595–603.
15. Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön M, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299:E506–15.
16. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Prevalence of uncomplicated obesity in an Italian obese population. Obes Res. 2005;13:1116–22.
17. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34:210–5.
18. Iacobellis G. True uncomplicated obesity is not related to increased left ventricular mass and systolic dysfunction. J Am Coll Cardiol. 2004;441:2257.
19. Sun K, Christine M, Kusminski M, Scherer P. Adipose tissue remodelling in obesity. J Clin Invest. 2011;121:2094–3101.
20. Cinti S. The adipose organ at a glance. Dis Model Mech. 2012;55:588–94.
21. Stefan N, Kantartzis S, Machann J, Schick F, Thamer C, Ritting K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–16.
22. Lundgren M, Svensson M, Lindmark S, Rendtrom M, Ruge T, Eriksson JW. Fat cell enlargement is an independent marker of insulin resistance and “hyperleptinemia”. Diabetologia. 2007;50:625–33.
23. Weyer C, Foley J, Bogardus C, Howard B, Ravussin E. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000;43:1498–506.
24. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun. 2003;301:578–82.
25. Dubois SG, Heilbronn LK, Smith SR, Albu JB, Kelley DE, Ravussin E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. Obesity (Silver Spring). 2006;14:1543–52.
26. van Tienen FH, van der Kallen CJ, Lindsey PJ, Wanders RJ, van Greevenbroek MM, Smeets HJ. Preadipocytes of type 2 diabetes subjects display an intrinsic gene expression profile of decreased differentiation capacity. Int J Obes (Lond). 2011;35:1154–64.
27. Wang MY, Grayburn P, Chen S, Ravazzola M, Orci L, Unger RH. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci USA. 2008;105:6139–44.
28. Arner P, Arner E, Hammarstedt A, Smith U. Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS One. 2011;6:e18284.
29. Gustafson B, Smith U. The Wnt inhibitor Dicckopf 1 and bone morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in human. Diabetes. 2012;61:1217–24.
30. Park HT, Lee ES, Cheon YP, Lee DR, Yang KS, Kim YT, et al. The relationship between fat depot-specific preadipocyte differentiation and metabolic syndrome in obese women. Clin Endocrinol (Oxf). 2012;76:59–66.
31. Smith U. Impaired (‘diabetic’) insulin signaling and action occur in fat cells long before glucose intolerance—is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord. 2002;26:897–904.
32. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2276–83.
33. Murdolo G, Smith U. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis. 2006;16(Suppl 1):S35–8.
34. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–9.
35. Iacobellis G, Ribaudo MC, Zappaterreno A, Vecci E, Tiberti C, Di Mario U, et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res. 2003;11:518–24.
36. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des. 2007;13:2180–4.
37. Iacobellis G, Sharma AM. Obesity and the heart: redefinition of the relationship. Obes Rev. 2007;8:35–9.
38. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450–7.
39. Salgado-Somoza A, Teijeira-Fernandez E, Rubio J, Couso E, Gonzalez-Juanatey JR, Eiras S. Coronary artery disease is associated with higher epicardial retinol-binding protein 4 (RBP4) and lower glucose transporter (GLUT) 4 levels in epicardial and subcutaneous adipose tissue. Clin Endocrinol (Oxf). 2011;76:51–8.
40. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab. 2006;91:4620–7.
41. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005;29:251–5.
42. Prati F, Arbustini E, Labellarte A, Sommariva L, Pawlowski T, Manzoli A, et al. Eccentric atherosclerotic plaques with positive remodelling have a pericardial distribution: a permissive role of epicardial fat? A three-dimensional intravascular ultrasound study of left anterior descending artery lesions. Eur Heart J. 2003;24:329–36.
43. Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM. Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol. 2011;146:452–4.
44. Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity. 2008;16:1693–7.
45. Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis. 2010;20:481–90.
46. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000;26:13.
47. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab. 2009;20:16–24.
48. Sethi JK. Activatin’ human adipose progenitors in obesity. Diabetes. 2010;59(10):2354–7.
49. McGavock J, Victor R, Unger M, Szczepaniak L. Adiposity if the heart, revised. Ann Intern Med. 2006;144:517–24.
50. Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2013;32:16–25.
51. Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G. Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. Am J Hypertens. 2013;27:146–56.
52. Smith HL, Willius FA. Adiposity of the heart. Arch Intern Med. 1933;52:410–28.
53. Soteriades E, Targino M, Talias M, Hauser R, Kawachi I, Christiani D, et al. Obesity and risk of LVH and ECG abnormalities in US fire fighters. J Occup Environ Med. 2011;53:867–71.
54. de Simone G, Devereux R, Roman M, Alderman M, Laragh J. Relation of obesity to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23:600–6.
55. Iacobellis G, Ribaudo MC, Leto G, Zappaterreno A, Vecci E, Di Mario U, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res. 2002;10:767–73.
56. de Simone G, Izzo R, De Luca N, Gerdts E. Left ventricular geometry in obesity: is it what we expect? Nutr Metab Cardiovasc Dis. 2013;23:905–12.
57. Du Cailar G, Ribstein J, Daures JP, Mimran A. Sodium and left ventricular mass in untreated hypertensive and normotensive subjects. Am J Physiol. 1992;263:H177–81.
58. du Cailar G, Ribstein J, Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens. 2002;15:222–9.
59. Strazzullo P, D’Elia L, Kandala N, Cappuccio F. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
60. Chinali M, de Simone G, Roman MJ, Lee ET, Best LG, Howard BV, et al. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol. 2006;47:2267–73.
61. Wong C, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick T. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110:3081–7.
62. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens. 2002;20:323–31.
63. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100:1802–27.
64. Devereux R, Roman M. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press Ltd; 1995. p. 409–24.
65. Levy D, Larson M, Vasan R, Kannel W, Ho K. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.
66. Verdecchia P, de Simone G. The heart in hypertension. A review. G Ital Cardiol. 1999;29:769–80.
67. Garcia J, Incerpi E. Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide. Arq Bras Cardiol. 2008;90:409–16.
68. de Simone G, Devereux RB. Method errors or unexplained biological information? Hypertension. 2010;56:e177–8.
69. de Simone G, Daniels S, Devereux R, Meyer R, Roman M, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251–60.
70. de Simone G, Kizer J, Chinali M, Roman M, Bella J, Best L, et al. Normalization for body size and population attributable risk of left ventricular hypertrophy: the strong heart study. Am J Hypertens. 2005;18:191–6.
71. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension. 2010;56:91–8.
72. Chirinos JA, Gillebert TC, Segers P, De Buyzere ML, Kronmal R, Raja MW, et al. Response to method errors or unexplained biological information? Hypertension. 2011;57:e9–10.
73. Paajanen T, Oksala N, Kuukasjarvi P, Karhunen P. Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis. Eur Heart J. 2010;31:1802–9.
74. de Simone G, Devereux R, Chinali M, Roman M, Barac A, Panza J, et al. Sex differences in obesity-related changes in left ventricular morphology: the strong heart study. J Hypertens. 2011;29:1431–8.
75. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Porcellati C. Early cardiac changes after menopause. Hypertension. 1998;32:764–9.
76. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res. 2004;12:887–8.
77. de Simone G, Pasanisi F, Ferrara A, Roman M, Lee E, Contaldo F, et al. Relative fat-free mass deficiency and left ventricular adaptation to obesity: The Strong Heart Study. Int J Cardiol. 2013;168:729–33.
78. Carpenter H. Myocardial fat infiltration. Am Heart J. 1962;63:491–6.
79. Chinali M, Aurigemma G. Refining patterns of left ventricular hypertrophy using cardiac MRI: “brother, can you spare a paradigm?”. Circ Cardiovasc Imaging. 2010;3:129–31.
80. Lund B, Gohlke-Barwolf C, Cramariuc D, Rossebo A, Rieck A, Gerdts E. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a simvastatin ezetimibe in aortic stenosis [SEAS] substudy). Am J Cardiol. 2010;105:1456–60.
81. de Simone G, Devereux RB, Chinali M, Roman MJ, Welty TK, Lee ET, et al. Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. J Hypertens. 2008;26:1868–74.
82. Turkbey E, McClelland R, Kronmal R, Burke G, Bild D, Tracy R, et al. The impact of obesity on the left ventricle: the multi-ethnic study of atherosclerosis (MESA). JACC Cardiovasc Imaging. 2010;3:266–74.
83. Woodiwiss A, Libhaber C, Majane O, Libhaber E, Maseko M, Norton G. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens. 2008;21:1144–51.
84. Asharafian H, Athanasiou T, le Roux C. Heart remodeling and obesity: the complexities and variations of cardiac geometry. Heart. 2011;97:171–2.
85. Celentano A, Palmieri V, Esposito ND, Pietropaolo I, Crivaro M, Mureddu GF, et al. Inappropriate left ventricular mass in normotensive and hypertensive patients. Am J Cardiol. 2001;87(361–363):A10.
86. Bo S, Mandrile C, Milanesio N, Pagani A, Gentile L, Gambino R, et al. Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. Nutr Metab Cardiovasc Dis. 2012;22:668–76.
87. Pickering T, Davidson K, Gerin W, Schwartz J. Masked hypertension. Hypertension. 2002;40:795–6.
88. Collis T, Devereux RB, Roman MJ, de Simone G, Yeh J, Howard BV, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation. 2001;103:820–5.
89. Aurigemma G, de Simone G, Fitzgibbons T. Cardiac remodeling in obesity. Circ Cardiovasc Imaging. 2013;6:142–52.
90. Verdecchia P, Angeli F, Achilli P, Castellani C, Broccatellia A, Gattobigio R, et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol. 2007;22:329–34.
91. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895–9.
92. Jordan J, Yumuk V, Schlaich M, Nilsson P, Zahorska-Markiewicz B, Grassi G, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047–55.
93. de Simone G, Devereux R, Izzo R, Girfoglio D, Lee E, Howard B, et al. Lack of reduction of left ventricular mass in treated hypertension: the Strong Heart Study. J Am Heart Assoc. 2013;2:1–8.
94. Verdecchia P, Angeli F. Reversal of left ventricular hypertrophy: what have recent trials taught us? Am J Cardiovasc Drugs. 2004;4:369–78.
95. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
96. Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment of hypertension. Diabetes Care. 2011;34(Suppl 2):S313–9.
97. Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, et al. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. Am J Cardiol. 2010;106:1270–6.
98. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, et al. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis. 2009;19:634–40.
99. Rider OJ, Francis JM, Ali MK, Petersen SE, Robinson M, Robson MD, et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol. 2009;54:718–26.
100. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J. 1996;131:313–9.
101. Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. BMJ. 1997;315:912–6.
102. Gerdts E, de Simone G, Lund BP, Okin PM, Wachtell K, Boman K, et al. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutr Metab Cardiovasc Dis. 2013;23:122–9.
103. Troy B, Pombo J, Rackley C. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation. 1972;45:602–11.
104. Devereux R, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613–8.
105. Devereux R, Alonso D, Lutas E, Gottlieb G, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.